Dabigatran - a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs

Dabigatran - a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs

Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/ or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular AF, exemplifies this issue. Whilst n...

Full description

Bibliographic Details
Main Authors: Rickard eMalmstrom, Brian eGodman, Eduardo eDiogene, Christoph eBaumgaertel, Marion eBennie, Iain eBishop, Anna eBrzezinska, Anna eBucsics, Stephen eCampbell, Alessandra eFerrario, Alexander eFinlayson, Jurij eFurst, Kristina eGaruoliene, Miguel eGomes, Iñaki eGutiérrez-Ibarluzea, Alan eHaycox, Krystyna eHviding, Harald eHerholz, Mikael eHoffmann, Saira eJan, Jan eJones, Roberta eJoppi, Marija eKalaba, Christina eKvalheim, Ott eLaius, Irene eLangner, Julie eLonsdale, Sven-Ake eLoov, Kamila eMalinowska, Laura eMcCullagh, Ken ePaterson, Vanda eMarkovic-Pekovic, Andrew eMartin, Jutta ePiessnegger, Gisbert eSelke, Catherine eSermet, Steven eSimoens, Faik Cankat Tulunay, Dominik eTomek, Luka eVoncina, Vera eVlahovic-Palcevski, Janet eWale, Michael eWilcock, Magda eWladysiuk, Menno van Woerkom, Corrine eZara, Lars L Gustafsson
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-05-01
Series:Frontiers in Pharmacology
Subjects:
Registries
Pharmacovigilance
dabigatran
critical drug evaluation
demand-side measures
drug and therapeutics committees
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00039/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00039/full

Similar Items